The direct relationship between the aging process and the incidence and prevalence of both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) implies that certain risk factors associated with the development of both diseases increase with the aging process. In particular, both diseases share an overly proliferative phenotype, suggesting that mechanisms that normally act to suppress cellular proliferation are disrupted or rendered dysfunctional as a consequence of the aging process. We propose that one such mechanism involves changes in the prostate microenvironment, which 'evolves' during the aging process and disrupts paracrine interactions between epithelial and associated stromal fibroblasts. We show that stromal fibroblasts isolated from the prostates of men 63-81 years of age at the time of surgery express and secrete higher levels of the CXCL12 chemokine compared with those isolated from younger men, and stimulate CXCR4-mediated signaling pathways that induce cellular proliferation. These studies represent an important first step towards a mechanistic elucidation of the role of aging in the etiology of benign and malignant prostatic diseases.
Introduction
Benign prostatic hyperplasia (BPH), or noncancerous enlargement of the prostate, is a common condition associated with aging in men (Meigs et al ., 2001; Verhamme et al ., 2002; Neuhouser et al ., 2004) . Studies both in vivo and in vitro have reported higher proliferative and lower apoptotic rates for epithelial cells from hyperplastic compared with normal prostates, suggesting that some proportion of increased prostate volume with age is attributable to increased epithelial cell densities (Berges et al ., 1995; Colombel et al ., 1998; Arenas et al ., 2001 ). However, the molecular mechanisms responsible for increased epithelial cell proliferation in hyperplastic human prostates are not well described. Work accomplished using rodent and rodent/human in vivo and in vitro models have suggested that paracrine interactions between glandular epithelial cells and adjacent fibroblastic stromal cells play an important role in the development of benign prostatic proliferative diseases (Thompson et al ., 1989; Merz et al ., 1991; Cunha et al ., 1996; Foster et al ., 1998; Hayward et al ., 1998; Song et al ., 2002) . Although useful for the study of various aspects of epithelial-stromal interactions, it is unclear whether rodent-based models accurately recapitulate such interactions in the human prostate. In order to create a humanbased system for the study of paracrine interactions during prostate tumorigenesis, some attempts have been made to mimic the in vivo system using human in vitro models. The most successful efforts to date have utilized cocultured normal human prostate-derived fibroblasts and the LNCaP prostate metastasis-derived cell line (Olumi et al ., 1998) . These studies clearly demonstrated that epithelial-stromal paracrine interactions were required for xenografted LNCaP cells to fully express the malignant phenotype and grow as tumors in athymic mice (Olumi et al ., 1998) .
The in vivo and in vitro studies described above show that epithelial-stromal interactions are crucial for the regulation of epithelial cell growth. However, because the etiologies of BPH and prostate cancer (PCa) are clearly associated with aging, it is important to determine whether epithelial-stromal interactions in the human prostate change over time and how such changes contribute to the development of hyperplasia and cancer. The studies reported here are the first to examine the effects of an aging microenvironment on paracrine interactions and prostatic epithelial cell proliferation. For these experiments, we utilized a novel in vitro model system for benign prostatic hyperplasia developed in our laboratory. The epithelial component of this model, N15C6 cells, was developed from immortalized primary normal prostate epithelial cells. The stromal component consisted of stromal fibroblastic cell populations cultured from the prostates of patients aged 40 -52 years (younger) or 63-81 years (older) at the time of surgery. Experiments accomplished using this model show that stromal fibroblast cells cultured from the prostates of older men were less able to suppress epithelial cell proliferation than those cultured from the prostates of younger men. Moreover, older fibroblasts expressed and secreted higher levels of the chemokine CXCL12 compared with younger fibroblasts, and the CXCL12 protein was mechanistically associated with enhanced epithelial cell proliferation. This is the first report to demonstrate that an aging microenvironment directly contributes to the disruption of normal human prostatic stromal-epithelial interactions and that this disruption causes enhanced epithelial cell proliferation similar to that observed in human BPH.
Results
Older fibroblasts are less able to repress epithelial cell proliferation than younger fibroblasts in vitro N15C6 human prostate epithelial cells demonstrated differential growth in conditioned media acquired from fibroblast cell populations originating from younger (40 -52 years old) compared with older (63-72 years old) patients (Fig. 1) . The average cell number for N15C6 cells grown in defined serum-free HIE conditioned media acquired from younger fibroblasts, 142 000 ( ± 16 400) cells, was significantly less than that for the same cells grown in defined serum-free HIE media alone, 235 990 ( ± 14 680) ( P < 0.001) (Fig. 1) . This suggested that conditioned media from younger fibroblast cells exerted a growth-suppressive effect on N15C6 prostate epithelial cells. In contrast, the average cell number for N15C6 cells grown in the presence of defined serumfree HIE conditioned media acquired from older fibroblasts, 209 000 ( ± 40 000) cells, was significantly higher than that for the same cells grown in the presence of defined serum-free HIE media acquired from younger fibroblasts ( P < 0.001) and was close to that obtained using defined serum-free HIE conditioned media alone (Fig. 1) . Conditioned media acquired from the fibroblasts of two older men, case no. 9303 (72 years old) and case no. 11084 (81 years old), elicited a proliferative response from N15C6 cells that actually exceeded the response observed using defined serum-free HIE media alone (Fig. 1) . Taken together, these results demonstrate that conditioned media from older prostate fibroblasts were less able to suppress N15C6 prostate epithelial cell growth, and in two instances actually induced N15C6 cell growth.
The fibroblasts used in the experiments described above were grown in culture from histologically verified benign tissues with one exception, case no. 091-08, which were grown from tissue containing malignant prostate glands. Interestingly, conditioned media from these cancer-associated fibroblasts were not growth suppressive, even though the tissue was acquired from a patient 49 years of age at the time of surgery and therefore defined in our study as a member of the 'younger' patient group.
Differential gene expression patterns distinguish older fibroblasts from younger prostate fibroblasts
The gene expression profiles of four fibroblast cell populations derived from younger patients, case nos 11033 (40 years old), 10063 (40 years old), 2396 (51 years old) and 1484 (52 years old) and of two derived from older patients, case nos 1442 (64 years old) and 8283 (71 years old), was obtained using Affymetrix U133A GeneChips and compared. These experiments identified 54 unique, differentially expressed, transcripts, with 41/54 (76%) up-regulated and 13/54 (24%) down-regulated in older compared with younger stromal fibroblasts. Nine of the transcripts that were up-regulated in RNA derived from older compared with younger prostate stromal fibroblasts encoded secreted proteins. Of these transcripts, the most highly up-regulated was for the gene encoding the secreted chemokine CXCL12, also known as SDF-1 (stromal derived factor 1), which was present at 3.4-fold higher levels in RNA prepared from older compared with younger stromal fibroblasts. Quantitative RT-PCR using a highly sensitive TaqMan assay measured 36-fold higher levels of CXCL12 transcript in older compared with younger fibroblasts ( P < 0.001), confirming that CXCL12 transcripts were more abundant in older prostate stromal fibroblasts.
CXCL12 is secreted by prostate stromal fibroblasts and induces prostate epithelial cell proliferation
An ELISA specific for CXCL12 confirmed that older stromal fibroblasts (populations 1442, 12154, 8283 and 10224) secreted Conditioned media from aged prostate stromal fibroblasts induce growth of N15C6 prostate epithelial cells. N15C6 prostate epithelial cells were grown for 96 h in 5% HIE, defined serum-free media (SF HIE) or SF HIE media grown for 48 h in the presence of fibroblast cell populations indicated by case number and patient age (in parentheses). Fibroblast population 091-08 was derived from cancer-associated stroma; the rest were derived from histologically benign tissues. Average cell growth in media from younger patients (aged 40-52; gray bars) is shown by solid line; average growth in media from older patients (aged 63-81; black bars) is shown by dashed line. Epithelial cell growth was significantly facilitated by media from older fibroblasts but inhibited by media from younger fibroblasts (P = 0.002).
higher levels of the CXCL12 protein into the culture media (3.70 -17.47 pg mL − 1 , or 0.47-2.24 p M ) compared with younger fibroblasts (populations 11033 and 3382; 3.71-0.65 pg mL − 1 , or 0.47-0.83 p M ). The same assay did not detect CXCL12 in culture media from N15C6 cells and detected very low levels of CXCL12 in culture media from LNCaP cells (3.9 ± 0.035 pg mL − 1 , or 0.50 p M ). These data demonstrated that older prostate fibroblasts secreted higher levels of CXCL12 than younger prostate fibroblasts or epithelial cells.
We next examined whether the addition of CXCL12 to defined serum-free media in the concentration range secreted by older prostate fibroblasts induced N15C6 or LNCaP prostate epithelial cell proliferation. As seen in Fig. 2 , the addition of CXCL12 at 1-3 p M for N15C6 cells, or 50 p M for LNCaP cells, was growth stimulatory and facilitated growth significantly above levels observed in defined serum-free media alone ( P < 0.001). Although the proliferative effect of low levels of CXCL12 was modest, the addition of higher concentrations of CXCL12 in both cases was clearly growth inhibitory. Together with the conditioned media experiments reported above, these results show that CXCL12 is secreted by human prostate stromal fibroblasts and directly stimulates human prostate epithelial cell proliferation at very low, picomolar concentrations.
CXCL12 stimulates phosphorylation of ERK 1/2 and NF-kappaB
Of the three major downstream signaling pathways stimulated by CXCR4/CXCL12 binding -PI3K/FAK, Ras/ERK and PI3K/NFkappaB -both the Ras-mediated ERK pathway and the PI3K-mediated NF-kappaB pathway are associated with cellular proliferation. We therefore tested whether CXCL12, which was observed to induce N15C6 and LNCaP cellular proliferation, also induced ERK and/or NF-kappaB activation. As seen in Fig. 3 , exposure of N15C6 cells to 1 p M , 10 p M or 1000 p M CXCL12 induced rapid, transient ERK phosphorylation and activation. ERK phosphorylation was maximal after 10 min of exposure to 1 or 10 p M CXCL12 and after just 5 min of exposure at 1000 p M CXCL12. Phosphorylation of the p65 subunit of NK-kappaB was not evident after exposure of N15C6 cells to 1 p M CXCL12 but was evident after 10 min exposure to 10 p M or 1000 p M CXCL12. CXCR4 levels were not detectably altered in cells exposed to CXCL12 over the same time period (Fig. 3) . These data show that even the very low levels of CXCL12 secreted by older prostate fibroblasts and associated with N15C6 and LNCaP cellular proliferation are sufficient for phosphorylation and activation of ERK 1/2 and NF-kappaB.
CXCL12 and CXCR4 proteins are expressed by human prostate tissues
Immunohistochemical analysis of a tissue microarray (TMA) was used to assess CXCL12 and CXCR4 protein expression in human prostate tissues (Fig. 4) . Benign glands (24 tissue cores), epithelial BPH (BPH-E, 65 cores), and malignant glands (77 cores) demonstrated both CXCL12 and CXCR4 protein expression. Benign glands demonstrated the highest levels of expression for both proteins (Fig. 5) . Malignant glands and BPH-E demonstrated equivalent CXCR4 expression, and CXCL12 levels were or LNCaP prostate epithelial cells were grown for 72 h in complete media (5% HIE for N15C6, 10% RPMI for LNCaP), defined serum-free HIE (SF) or SF supplemented to the indicated concentration of CXCL12. N15C6 cellular proliferation was induced above SF levels at 1-3 pM CXCL12 but was suppressed at 1000 pM CXCL12, whereas LNCaP proliferation was induced at 50 pM CXCL12 (P < 0.001). approximately half that of CXCR4 levels in the same tissues (Fig. 5) . The expression pattern for CXCR4 was cytoplasmic and/or membraneous (Fig. 4A,B,D) with the exception of 14/65 (21%) samples of BPH-E, which demonstrated strong nuclear staining (Fig. 4C) . The expression pattern for CXCL12 appeared to be exclusively membrane-bound, and likely reflected detection of the protein bound to the CXCR4 receptor (Fig. 4E-G) .
Discussion
Several studies have shown that epithelial-stromal interactions are crucial for the regulation of epithelial cell growth. We have hypothesized that epithelial-stromal interactions in the human prostate change over time and that these changes may contribute to the development of hyperplasia and cancer. To test this hypothesis, we have examined the effects of an aging microenvironment on paracrine interactions and prostatic epithelial cell proliferation using a novel in vitro model system for benign prostatic hyperplasia developed in our laboratory. The results of these experiments show that the prostate stroma overall exerts a repressive effect on prostate epithelial cell growth. This finding is consistent with the observation that paracrine interactions between human prostate epithelial cells and rat urogenital sinus mesenchyme act homeostatically to maintain both cell types in a nonproliferative, differentiated state Hayward et al ., 1998) . Even so, the results of our studies also show that growth of the N15C6 human prostate epithelial cells in media conditioned by older (patients aged 63-81 years) stromal fibroblasts was clearly enhanced compared with growth in media conditioned by younger (patients aged 40-52 years) fibroblasts. In two instances (cases nos 9303 and 11084), N15C6 epithelial cell growth in media conditioned by older prostate fibroblasts actually exceeded levels obtained in complete media (5% HIE). This implies that suppression of epithelial cell proliferation is less efficient in the aging prostate, and that this reduction in efficiency can be directly attributable to paracrine interactions with aging stromal fibroblasts. Interestingly, conditioned media from the single cancer-associated fibroblast population were not growth suppressive, even though the tissue was acquired from a patient 49 years of age at the time of surgery and therefore defined in our study as a member of the 'younger' patient group. This observation is consistent with other studies suggesting that cancer-associated fibroblasts may facilitate prostate epithelial cell proliferation and transformation (Olumi et al ., 1996 (Olumi et al ., , 1998 .
Our studies also showed that older prostate stromal fibroblasts transcribe the CXCL12 gene and secrete higher levels of the CXCL12 protein compared with younger stromal fibroblasts. Moreover, 'add back' assays demonstrated that low, picomolar concentrations of CXCL12 directly stimulate human prostate epithelial cell proliferation, and that this effect is likely mediated through phosphorylation and activation of ERK 1/2 and NF-kappaB. The chemokine CXCL12 and its receptor, CXCR4, are known to stimulate lymphocyte proliferation and to mediate lymphocyte trafficking (Nagasawa et al ., 1994; Moser & Loetscher, 2001 ). These molecules have also been recently implicated in cancer cell migration and invasion. Cultured prostate cancer cells have been shown to migrate and invade through extracellular matrix and to migrate across bone marrow endothelial cell monolayers in response to CXCL12, activities that can be blocked by pretreatment with antibody against the receptor, CXCR4 (Taichman et al ., 2002; Mochizuki et al ., 2004; Singh et al ., 2004) . Cultured breast cancer cells demonstrate enhanced chemotaxis, chemoinvasion and adhesive properties in response to CXCL12, and cells 'knocked down' for CXCR4 transcripts demonstrate significantly reduced ability to invade through Matrigel in vitro (Chen et al ., 2003; Fernandis et al ., 2004; Lapteva et al ., 2005) . Taken together, these studies indicate a role for CXCL12/CXCR4 interactions in breast and prostate cancer cell migration and invasion. Several of these reports also noted that breast and prostate cancer cells did not proliferate in response to nanomolar levels of CXCL12, although these levels were associated with motility and invasion (Taichman et al ., 2002; Fernandis et al ., 2004; Mochizuki et al ., 2004; Singh et al ., 2004) . We now report that CXCL12 levels as low as 1-5 p M for N15C6 and 50-500 p M for LNCaP prostate epithelial cells stimulate cellular proliferation and that higher levels are clearly growth inhibitory. Together with the studies cited above, this finding suggests that CXCL12 exerts a concentrationdependent dual effect on prostate epithelial cell biology, i.e. lower, picomolar levels stimulate proliferation whereas higher, nanomolar levels repress proliferation but induce motility and invasiveness. These results are consistent with roles for CXCL12/ CXCR4 interactions in the etiologies of both benign proliferative disease (BPH) and malignant disease (PCa) in the prostate. Moreover, our observations that low, picomolar levels of CXCL12 equivalent to those secreted by older prostate fibroblasts are associated with prostate epithelial cell proliferation, as well as with activation of ERK 1/2 and NF-kappaB, mechanistically links CXCL12/CXCR4 binding, epithelial/stromal fibroblast paracrine interactions, and epithelial cellular proliferation in the context of an aging microenvironment.
Although the proliferative effects observed for prostate epithelial cells after growth in picomolar levels of CXCL12 were modest, our studies identified several transcripts corresponding to growth-stimulatory secreted proteins. Therefore, the incremental induction of cellular proliferation by CXCL12 likely reflects the effects of just one of several growth-stimulatory factors secreted by aging prostate fibroblasts. As these factors are validated and tested using our in vitro system, it is likely that, together, they will recapitulate the significant growth-stimulatory effects observed after exposure of prostate epithelial cells to media conditioned by aging fibroblasts.
The immunohistochemical analyses reported here demonstrate CXCR4 protein expression and less abundant CXCL12 expression in epithelial cells associated with benign glands, BPH nodules characterized by epithelial hyperplasia (BPH-E) and malignant glands, but not in BPH nodules characterized by stromal hyperplasia (BPH-S). CXCR4 demonstrated cytoplasmic and membraneous staining whereas CXCL12 appeared to be exclusively membrane-bound, and likely reflected detection of the protein bound to the CXCR4 receptor. The lack of expression of both CXCR4 and CXCL12 in BPH-S tissues indicates that CXCR4 protein is not expressed in these tissues and that CXCL12 is virtually undetectable in the absence of its receptor. Interestingly, glandular epithelial cells within BPH-E tissue sections demonstrated the most diverse patterns of CXCR4 expression, with 14/65 (21%) of samples exhibiting exclusively nuclear staining, 20/65 (31%) exhibiting both cytoplasmic and nuclear staining, and 25/65 (38%) exhibiting exclusively cytoplasmic staining. A recent retrospective study of tissues resected from stage I non-small-cell lung cancer patients described strong nuclear staining in 29.8% of tumors, and showed that nuclear localization for CXCR4 was significantly associated with longer patient survival (Spano et al ., 2004). It is known that CXCR4 undergoes endocytosis mediated by clathrin-coated pits, that this mechanism permits recycling of CXCR4 between the cell membrane and endosomal compartments in hematopoetic progenitor cells and T-cells, and that this process is constitutive in some cells but can be accelerated by CXCL12 (Signoret et al ., 1997; Zhang et al ., 2004) . Whether the nuclear localization of CXCR4 observed here and by others is due to a disruption or evasion of normal CXCR4 recycling, or to an independent and alternate mechanism, remains to be elucidated.
In summary, these studies show that stromal fibroblasts from the prostates of older men are less able to suppress epithelial cell proliferation than those from younger men, that this effect is at least partially mediated by oversecretion of the CXCL12 chemokine, and that low, picomolar levels of CXCL12 equivalent to those secreted by older prostate stromal fibroblasts initiates a signaling cascade that triggers epithelial cell proliferation. This work represents an important first step towards a mechanistic elucidation of the role of aging in the etiology of benign and malignant prostatic diseases. Future studies focusing on how the balance of growth factors and growth repressors secreted by stromal fibroblasts becomes altered within the context of an aging microenvironment will further elucidate how the aging process directly contributes to the development of hyperplasia and neoplasia in the human prostate.
Experimental procedures Establishment of cell cultures
All tissue acquisition and processing protocols conformed to those reviewed and approved by the University of Michigan Institutional Review Board. Normal prostate tissue samples were obtained aseptically from patients undergoing radical prostatectomy or cystoprostatectomy after cancer diagnosis. Tissue was taken exclusively from the transitional zone of the prostate surrounding the urethra to facilitate the isolation of fibroblasts associated with benign prostatic hyperplasia (BPH). A small slice of the tissue piece ( ∼ 25%) was fixed in 10% formalin for immunohistochemical examination. The remaining tissue was minced into pieces of < 1 mm in size, digested overnight in 1 mg mL − 1 collagenase III (Worthington Biochemicals, Lakewood, NJ, USA) at 37 ° C with gentle shaking, spun down, resuspended and plated in 5% HIE media [Ham's F12 (Mediatech Inc., Herndon, VA, USA) with 5% FBS (Invitrogen Life Technologies Inc., Carlsbad, CA, USA), 5 µ g mL − 1 insulin, 10 ng mL − 1 EGF, 1 µ g mL − 1 hydrocortisone (Sigma Chemical Co., St. Louis, MO, USA). Subcultured fibroblast cell populations were assessed by immunohistochemistry using monoclonal antibodies to vimentin or alpha-actin (SigmaAldrich, St. Louis, MO, USA) to distinguish stromal fibroblastic cells from smooth muscle cells, respectively. The fibroblast cell populations used in these studies were stained uniformly for vimentin but not alpha-actin and were maintained in 5% HIE. The N15C6 cell line was developed as described previously (Macoska et al., 2004; Begley et al., 2005) . For conditioned media experiments, N15C6 cells were grown either in defined serum-free HIE media supplemented to 5 mM ethanolamine (Sigma-Aldrich), 10 mM HEPES (Sigma-Aldrich), 5 µg µL −1 transferrin (Sigma-Aldrich), 10 µM 3,3′,5-triiodo-L-thyronine (SigmaAldrich), 50 µM sodium selenite (Sigma-Aldrich), 0.1% BSA (JRH Biosciences Lenexa, KS, USA), 0.05 mg mL −1 gentamycin (Gibco, Carlsbad, CA, USA), and 0.5 µg mL −1 fungizone (Cambrex Bioscience, Walkersville, MD, USA), or in defined serum-free HIE conditioned media produced through the incubation of fibroblast cell populations in supplemented serum-free HIE media over a 48-h period. Conditioned media were harvested from all fibroblast cell populations at passages 1-3 with the exception of no. 2396 (passage 4), no. 3294 and no. 10063 (passage 5), and no. 11033 and no. 3382 (passage 11).
Proliferation assays
Cellular proliferation was assessed after plating cells at 50 000 cell/well in triplicate in six-well plates and counting cells after 24 and 96 h of incubation in complete media, serum-free media or serum-free prostate stromal fibroblast conditioned media, as described previously (Macoska et al., 2004) . Averages and standard deviations of cell number were calculated for each time point under each media condition. To assess the effects of exogenous CXCL12 on cellular proliferation, recombinant human SDF1 alpha/CXCL12 (R & D Systems, 350-NS) was added at the desired concentration in 1 mL SF HIE (or 1 mL SF HIE alone for control) to each well. The cells were counted at 24 and 96 h growth and re-fed at 48 and 72 h growth. Cell counts were normalized to 50 000 cells at 24 h to account for any plating discrepancies.
Affymetrix U133A GeneChip data acquisition
RNA was purified from trypsinized cultured cells by homogenization in Trizol (Invitrogen, Carlsbad, CA, USA) and additional processing using the RNeasy (QIAGEN, Valencia, CA, USA) cleanup procedure. Ten micrograms of RNA obtained from tissues or cell line was used to obtain labeled cRNA following the Affymetrix standard protocol. Expression intensity values for each gene were estimated using a method called Robust Multi-array Average (RMA) using tools available through Bioconductor (www.bioconductor.org). GeneChip gene expression values were normalized using a quantile normalization procedure.
Quantitative real-time PCR
All quantitative real-time assays were conducted with an Applied Biosystems 7900HT instrument and reagents. 
ELISA assays
Fibroblasts were grown in 0.01% BSA defined HIE for 3 days. Fibroblast-conditioned media were collected, serially concentrated using Centriplus Centrifugal Filters (Millipore, Billerica, MA, USA) with a 3 kDa molecular weight cutoff, and assessed using the CXCL12/SDF1-alpha ELISA system (R & D Systems). All reactions were performed in duplicate and the resulting values averaged.
Western blot analysis
Cells were lysed, proteins resolved by electrophoresis and electroblotting was carried out as described previously (Chaib et al., 2001) . Proteins were detected using antibodies against phospho-ERK1/2 (Cell Signaling no. 9101), total ERK1/2 (Cell Signaling, no. 9102), CXCR4 (Abcam no. ab2074), phospho-p65 (Rockland no. 100-401-264), total p65 (Rockland no. 100-4165), or beta-actin (Santa Cruz no. sc-1615), in conjunction with an ECL detection system.
Construction of tissue microarray (TMA) and immunohistochemistry
A TMA was constructed from 31 radical prostatectomy specimens to represent benign prostate tissues [number of cores (N ) = 24]; benign prostatic hyperplasia epithelial tissues (BPH-E) (N = 65); benign prostatic hyperplasia stromal tissue (BPH-S) (N = 102) and prostate cancer (N = 77). Antigen retrieval was performed in citrate buffer (10 mM, pH 6.0) using a microwave pressure cooker. The CXCR4 antibody (Abcam, ab2074) was used at 1 : 50 and CXCL12 (R & D Systems, MAB350) at 1 : 100. Digital images were acquired with the BLISS Imaging System (Bacus Laboratory, Lombard, IL, USA). Immunostaining intensity was recorded as absent (1), weak (2), moderate (3), or strong (4) and as the percentage of cells staining on a scale of 1-100%. The product of each (intensity × percentage) was used to calculate a staining score for each tissue. Scoring was performed in a blinded fashion using the Profiler Web-based telepathology system (http:// pvdb.path.med.umich.edu/htma/profiler/index.jsp).
Statistical analysis
GeneChip expression values were analyzed using a t-statistic test and by calculation of fold change between data sets. Genes that exhibited both a large t-statistic (> 10.0) and a large fold change (> 2.0) were considered to be differentially expressed. All other data were assessed by t-test or analysis of variance with P < 0.05 considered statistically significant.
